May 15, 2015. By Heidi Turner.
Read [ Vytorin Has a Complex History ]
Washington, DC The new study on Vytorin may be out, and it may signal good news for its drug maker, but as far back as 2008, there were serious concerns about how Merck and Schering-Plough planned to study potential Vytorin side effects. Concerns were so high that on March 31, 2008, Senator Chuck Grassley sent a letter to Merck and Schering-Plough outlining his worries.
April 15, 2015. By Heidi Turner.
Read [ Merck Pushes Positive Vytorin Results ]
San Diego, CA As more information on a recent Vytorin study is released, Merck has continued to tout the positive findings of that study. Vytorin side effects have been at the heart of Vytorin lawsuits, alleging patients were put at risk of health problems due to their use of the drug.
March 27, 2015. By Gordon Gibb.
Read [ Vytorin Brightens with IMPROVE-IT, but Vytorin Lawsuits Remain ]
San Diego, CA The folks at Merck & Co. and their Vytorin partner Schering-Plough Corp. can be forgiven if they are enjoying the re-birth of Vytorin and the accompanying optimism after enduring the scorn that accompanied the delayed release of the ENHANCE study in 2008. The most recent “IMPROVE-IT” study was designed to foster a better outcome, and the study delivered. The future of Vytorin is much rosier. However, questions surrounding Vytorin side effects remain. And many a Vytorin lawsuit stemming from the two-year delay in releasing the ENHANCE results continues to hang over Merck’s head.
January 29, 2015. By Gordon Gibb.
Read [ Zetia and Vytorin: Never Say Never ]
Washington, DC If there is one thing to be said about pharmaceutical companies, it remains that they never, ever give up. Not until a product is deemed so unsafe that it is physically pulled from the market, will a manufacturer finally wave the white flag. This is especially true in the statin sector, which is the biggest piece of the pie with potential to get even bigger. Thus, when Zetia and Vytorin came under attack in 2008, manufacturers Merck & Co. and Schering-Plough basically bided their time.
December 29, 2014. By Heidi Turner.
Read [ Examining the IMPROVE-IT Vytorin Results ]
Chicago, IL Last month’s release of the Vytorin IMPROVE-IT study brought positive attention to Merck, whose drug has been under fire thanks to reported Vytorin side effects and concerns that Vytorin was no more effective than a statin on its own. But there are still concerns about Vytorin, and it should be noted that previous studies have not always found benefit to Vytorin.
November 20, 2014. By Heidi Turner.
Read [ Study Finds Benefit to Vytorin, but Is It Credible? ]
Chicago, IL A study released today suggests that Vytorin, a drug that combines Zetia and Zocor, is more effective than Zetia alone at preventing heart attack and other heart-related health problems. The study is good news for Merck, who has been under fire for its handling of Vytorin. But other previous studies gave conflicting results regarding Vytorin’s effectiveness, and there are concerns about the delays in releasing this study, including a switch in primary endpoints, which could affect how positive the results actually are.
October 29, 2014. By Heidi Turner.
Read [ Medical Industry Waits for Study on Vytorin ]
Washington, DC Less than a month away is the expected deadline for the medical world to hear the results of a study on Vytorin. The study has been undertaken to add to the published literature about Vytorin side effects and Vytorin effectiveness. So far, at least two studies regarding the drug, which combines ezetimibe (Zetia) and simvastatin (Zocor), have not shown that Vytorin is any more effective than Zocor alone.
September 27, 2014. By Heidi Turner.
Read [ New Vytorin Study Results on the Way ]
Washington, DC Another study is set to be released regarding the effectiveness of Vytorin, a drug that combines ezetimibe (known by the brand name Zetia) and simvastatin (known by the brand name Zocor). Whether the study will confirm previous findings that question the effectiveness of combining Zetia and Zocor is not known. Some previous studies have failed to show that the two drugs combined are more effective than Zocor alone or Zocor and a different statin.
August 31, 2014. By Gordon Gibb.
Read [ Of All Vytorin Side Effects, Potential for Cancer Is Getting Traction ]
Washington, DC One can’t help but forgive anyone filing a Vytorin lawsuit, due to not only the potential for various harms related to possible Vytorin side effects, but to the very culture that sees drugs such as these approved in the first place.
March 7, 2013. By Heidi Turner.
Read [ Attorney Ben Stewart: Vytorin “Controversial” ]
Whitehouse Station, NJ With a study about Vytorin expected in the next month or two, patients deciding whether or not to use the medication must rely on previous studies regarding Vytorin side effects. Those studies suggest that Vytorin can cause serious adverse reactions, according to Ben Stewart, attorney at Stewart Law, PLLC. Although there are no personal injury lawsuits currently working their way through the courts, that could change, depending on what the anticipated study shows.
- Will We Be Left Waiting for Latest Vytorin Trial Results? By Gordon Gibb (Apr-12-11)
- Niacin Found to Be More Effective than Vytorin at Lowering Cholesterol By Charles Benson (Nov-26-09)
- ARBITER 6-HALTS Results Not Good for Zetia By Heidi Turner (Nov-17-09)
- Vytorin Kidney Failure: "It's going to end my life soon." By Paul Halpern (Mar-12-08)